COMMUNIQUÉS West-GlobeNewswire

Acentra Health’s Dr. Ryan Bosch Named a 2025 Innovator in Health Care by Washington Business Journal
30/09/2025
Award honors Dr. Bosch as one of Greater Washington’s top leaders for delivering the innovation, data strategy, and clinical insight needed to meet healthcare’s biggest challenges MCLEAN, Va., Sept. 30, 2025 (GLOBE [...]
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
30/09/2025
Strategic Acquisition Bolsters AI-Driven Healthcare Innovation, Positioning Fifty 1 Labs as a Leader in Clinical Data Analytics VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs Inc [...]
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
30/09/2025
GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are [...]
HNL Lab Medicine Introduces Self-Collected HPV Test to Increase Privacy and Access
30/09/2025
ALLENTOWN, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HNL Lab Medicine is pleased to offer a new self-collected HPV test that enhances patient privacy and convenience. This test detects 14 high-risk strains of Human [...]
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
30/09/2025
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo [...]
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
30/09/2025
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
30/09/2025
ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia. ODM-105 (tasipimidine) was [...]
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
30/09/2025
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how [...]
Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway
30/09/2025
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologic drug therapies for hard-to-heal wounds, today announced that it is scheduled [...]
Lung Health Foundation: 'Canadian Charities Face Obstacles as the Postal Strike Threatens to Block Millions in Essential Year-End Donations'
30/09/2025
Canada’s Largest Charity Dedicated to Lung Health Responds to the Launch of a Canada Post Strike TORONTO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- A postal strike in Canada disproportionately threatens the lifeblood of [...]
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
30/09/2025
Focal One ® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network AUSTIN, Texas [...]
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
30/09/2025
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
30/09/2025
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the [...]
Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings
30/09/2025
NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance [...]
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
30/09/2025
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses observed out to 18 [...]
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
30/09/2025
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2 clinical trial in patients with cognitive impairment associated with schizophrenia [...]
Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto
30/09/2025
Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the successful closing of a $41 million private investment in public equity (PIPE [...]
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
30/09/2025
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
30/09/2025
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 [...]

Pages